This website uses cookies to enhance the user experience.
N

NORGENOTECH AS897 365 812

Research
Limited company
Ullernchausséen 64 0379 OSLO, Norge

NORGENOTECH AS

NorgenoTech | |

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
14 years
since Sep 20, 2011
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
127,000
1 share class
Total number of shareholders
6
persons
Belongs to group of

Financials

Total operating income 2024
721,579
NOK
Annual total result 2024
-208,240
NOK
Total equity 2024
291,904
NOK
Last update: Jul 26, 2025

Management

Board

NameRoleShares
Contact Person, Chairman
4.13 %
directly
Board Member-
Board Member
10.43 %
directly
Board Member
25.39 %
directly

Others

NameRoleShares
I
I M RUUD REGNSKAP AS
Accountant-

Top 10 individual shareholders

NameRoleShares
-
49.61 %
directly
Board Member
25.39 %
directly
Board Member
10.43 %
directly
-
7.09 %
directly
Contact Person, Chairman
4.13 %
directly
-
3.35 %
directly
Last update: Jun 7, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
Ordinary shares
63,000
49.61 %
Ordinary shares
32,250
25.39 %
Ordinary shares
13,250
10.43 %
Ordinary shares
9,000
7.09 %
Ordinary shares
5,250
4.13 %
Ordinary shares
4,250
3.35 %

Shares owned by the NORGENOTECH AS

NameShare classTotal number of sharesShare
C
COMET BIOTECH AS
Ordinary shares
100,000
100 %
Last update: Jun 2, 2025

Group structure

  • Total operating income 2024: NOK 721,579
    Operating profit 2024: NOK -248,241
    Employees: 0

Financials

in NOK

Summary

Year2024202320222021
Total operating income
721,579
3,266,959
3,538,415
3,759,824
Annual Total Result
-208,240
473,619
-246,617
17,570
Total assets
811,031
1,262,848
1,271,181
1,934,344
Total liabilities
519,128
762,704
1,244,656
1,661,203
Total equity
291,904
500,143
26,525
273,141

P&L

Year2024202320222021
Total operating income
721,579
3,266,959
3,538,415
3,759,824
Total operating costs
969,820
2,601,741
3,831,056
3,710,742
Operating result
-248,241
665,218
-292,641
49,082
Financial income/costs
-9,834
-56,070
-20,890
-27,606
Profit before tax
-258,075
609,148
-313,532
21,476
Total tax & extraordinary income/cost
-49,835
135,529
-66,915
3,906
Annual Total Result
-208,240
473,619
-246,617
17,570

Balance overview

Year2024202320222021
Total fixed assets
251,661
205,389
355,982
317,857
Total current assets
559,370
1,057,459
915,198
1,616,487
Total assets
811,031
1,262,848
1,271,181
1,934,344
Short term debt
519,128
762,704
1,244,656
1,661,203
Long term debt
0
0
0
0
Total liabilities
519,128
762,704
1,244,656
1,661,203
Contributed capital
136,680
136,680
136,680
136,680
Retained earnings
155,224
363,463
-110,155
136,461
Total equity
291,904
500,143
26,525
273,141
Total equity and liabilities
811,031
1,262,848
1,271,181
1,934,344

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology